62nd ASH Annual Meeting and Exposition: 102. Regulation of Iron Metabolism: Poster I

Oral and Poster Abstracts
Poster

Adult, Anemias, antibodies, apoptosis, Biological, Diseases, Non-Biological, chemical interactions, Therapies, Adverse Events, Genetic Disorders, Biological Processes, enzyme inhibitors, iron deficiency, erythropoiesis, Study Population, Clinically relevant, pharmacology, inflammation, iron metabolism, iron transport, pathogenesis, signal transduction

766

Hemoglobin (Hb) Correction with Roxadustat Is Associated with Improved Iron Homeostasis in Patients with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

Steven Fishbane¹^*, Chaim Charytan²^*, Dustin Little³^*, Stefan Tham⁴^*, Robert Leong⁵^* and Pablo E Pergola⁶^*

¹Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
²New York Hospital Queens, Division of Nephrology, Flushing, NY
³Clinical Research, AstraZeneca, Gaithersburg, MD
⁴Clinical Research, AstraZeneca, Gothenburg, Sweden
⁵FibroGen Inc., San Francisco
⁶Renal Associates PA, San Antonio, TX

767

Iron-Dependent Apoptosis Causes Embryotoxicity in Inflamed and Obese Pregnancy

Allison Fisher¹^*, Veena Sangkhae, PhD^2,3^*, Nicolaos J. Palaskas, MD⁴^*, Tomas Ganz, MD, PhD⁵ and Elizabeta Nemeth, PhD⁶

¹David Geffen School of Medicine At UCLA, Los Angeles, CA
²Center for Iron DIsorders, University of California Los Angeles, Los Angeles, CA
³Center for Iron Disorders, University of California Los Angeles, Los Angeles, CA
⁴UCLA Medical Center, Los Angeles, CA
⁵Center for Iron Disorders, University of California, Los Angeles, Los Angeles, CA
⁶Center for Iron Disorders, David Geffen School of Medicine at UCLA, Los Angeles, CA

768

Transcriptional Regulation of Ferroptosis in X-Linked Sideroblastic Anemia

Koya Ono, MD¹^*, Tohru Fujiwara, MD, PhD^1,2, Kei Saito, MD, PhD¹^*, Chie Suzuki²^*, Noriyuki Takahashi²^*, Yan Yan³^*, Sayaka Sano, MD¹^*, Koichi Onodera, MD, PhD¹^*, Satoshi Ichikawa, MD, PhD⁴^*, Noriko Fukuhara, MD, PhD¹, Yasushi Onishi, MD, PhD¹^*, Hisayuki Yokoyama, MD, PhD¹, Yukio Nakamura, MD, PhD⁵^* and Hideo Harigae, MD, PhD^1,2

¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan
²Laboratory Diagnostics, Tohoku University Hospital, Sendai, Japan
³Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan
⁴Department of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, Japan
⁵Cell Engineering Division, RIKEN BioResource Research Center, Tsukuba, Japan

769

Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants

Claudia Ordonez, MD¹^*, Snyder Ben, MD^2,3^*, Rachel Barger¹^*, Timna Serino¹^*, Claire C Tseng, PhD¹^*, Christopher Rovaldi, M.Sc⁴^*, Jenn Lachey¹^* and Jasbir Seehra¹^*

¹Keros Therapeutics, Lexington, MA
²Nucleus Network, Melbourne, Australia
³The Alfred Hospital, Melbourne, Australia
⁴NSBiopharma, Marblehead, MA

770

Persistent Hypophosphatemia after Ferric Carboxymaltose Is Associated with Persistent Changes in Biomarkers of Bone Metabolism

Myles Wolf, MD, MMsc¹^*, Benedikt Schaefer, MD²^* and Heinz Zoller, MD²^*

¹Division of Nephrology, Duke University School of Medicine, Durham, NC
²Department of Medicine I, Gastroenterology, Hepatology and Endocrinology, Medical University of Innsbruck, Innsbruck, Austria

771

Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron

Thomas A Backus^*, Natalia Medeiros^*, Evan Lema^*, Ffolliott Fisher^*, Jasbir Seehra^* and Jennifer Lachey^*

Keros Therapeutics, Lexington, MA

772

Intravenous Iron Infusion Administration Schedule and Hematologic Response; A Single-Center Retrospective Cohort Study

Melissa T. Maltez, MD¹^* and Johnathan P. Mack, MD, MSc²

¹University of Ottawa, Ottawa, ON, Canada
²University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada

773

Hepcidin and Erythroferrone Levels in p.C282Y Homozygotes and Control Subjects in the HEIRS Study

Gordon D. McLaren, MD¹, Tomas Ganz, MD, PhD², Elizabeta Nemeth, PhD^3,4, Wen-Pin Chen, MS⁵^* and Christine E. McLaren, PhD⁶

¹Division of Hematology/Oncology, University of California, Irvine, Irvine, CA
²Departments of Medicine and Pathology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
³University of California-Los Angeles, Los Angeles, CA
⁴Center for Iron Disorders, David Geffen School of Medicine at UCLA, Los Angeles, CA
⁵Chao Family Comprehensive Cancer Center, Orange, CA
⁶Department of Medicine, University of California, Irvine, Irvine, CA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

102.P1.24 102. Regulation of Iron Metabolism: Poster I